Gilead Sciences agreed to acquire Ouro Medicines in a deal valued at about $2.17 billion, adding gamgertamig (OM336), a BCMAxCD3 T-cell engager, to its autoimmune pipeline. The transaction structure includes $1.675 billion in upfront cash and up to $500 million in contingent milestone payments. Separately, Gilead is in advanced discussions with Galapagos to adjust the existing partnership around gamgertamig upon close. Gilead framed the acquisition as a way to strengthen its inflammation and cell-therapy capabilities while positioning the program for future registrational development beginning in 2027 after ongoing early-phase data and regulatory designations.